Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spont...
Saved in:
Main Authors: | Catherine King, Fionnuala Cox, Anne Sloan, Patricia McCrea, J.David Edgar, Niall Conlon |
---|---|
Format: | article |
Language: | EN |
Published: |
Elsevier
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/55bf881013204d3b9915fc5d9d0dba69 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
by: Davide Stefano Sardina, et al.
Published: (2021) -
Two decades with omalizumab: what we still have to learn
by: Incorvaia C, et al.
Published: (2018) -
Aetiology of urticaria in children
by: S. N. Buinova, et al.
Published: (2017) -
Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
by: Elisa Meucci, et al.
Published: (2021) -
Guía clínica chilena de urticaria crónica espontánea
by: Aguilera-Insunza,Raquel, et al.
Published: (2018)